Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
暂无分享,去创建一个
[1] F. Wolfe,et al. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.
[2] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[3] J. Rubins,et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. , 2004, Seminars in arthritis and rheumatism.
[4] F. Wolfe,et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. , 2004, Arthritis and rheumatism.
[5] D. Boumpas,et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit , 2004, Annals of the rheumatic diseases.
[6] J. Daurès,et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[7] P. Lipsky,et al. Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[8] Kathleen A Snella,et al. Listeria Meningitis Associated with Infliximab , 2004, The Annals of pharmacotherapy.
[9] Arl Medford,et al. British Thoracic Society , 2004 .
[10] L. Jacobsson,et al. Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent , 2004 .
[11] J. Pawlotsky,et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. , 2004, The Journal of rheumatology.
[12] N. Ragni,et al. Inflammatory bowel disease: management issues during pregnancy , 2004, Archives of Gynecology and Obstetrics.
[13] G. Sarosi,et al. Pulmonary Cryptococcosis After Initiation of Anti-Tumor Necrosis Factor-α Therapy , 2003 .
[14] V. Strand,et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.
[15] M. Fitzcharles,et al. Induction of autoantibodies during prolonged treatment with infliximab. , 2003, Journal of Rheumatology.
[16] A. Gottlieb,et al. Etanercept therapy in patients with autoimmunity and hepatitis C , 2003, The Journal of dermatological treatment.
[17] L. Klareskog,et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense , 2003, Annals of the rheumatic diseases.
[18] J. Kuruvilla,et al. Aplastic anemia following administration of a tumor necrosis factor‐α inhibitor , 2003 .
[19] C. Denton,et al. Etanercept‐induced systemic lupus erythematosus , 2003, Clinical and experimental dermatology.
[20] S. Helfgott,et al. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? , 2003, The Journal of rheumatology.
[21] R. Andrade,et al. Acute leukemia after infliximab therapy , 2003, American Journal of Gastroenterology.
[22] M. Wener,et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.
[23] M. Hochberg,et al. Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[24] P. V. van Riel,et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[25] G. Gottlieb,et al. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] P. Emery,et al. Role of biologics in early arthritis. , 2003, Clinical and experimental rheumatology.
[27] E. Keystone,et al. Role of infliximab in the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.
[28] M. Genovese,et al. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. , 2003, Clinical and experimental rheumatology.
[29] E. Keystone,et al. Role of adalimumab in the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.
[30] C. Richart,et al. Severe neutropenia and thrombocytopenia associated with infliximab. , 2003, Annals of internal medicine.
[31] J. Gómez-Reino,et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.
[32] M. Michel,et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. , 2003, The Journal of rheumatology.
[33] J. Block,et al. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. , 2003, Clinical and experimental rheumatology.
[34] H. Nossent,et al. Acute myelogenous leukaemia following etanercept therapy. , 2003, Rheumatology.
[35] D. Craven,et al. Invasive Pulmonary Aspergillosis Soon After Therapy With Infliximab, a Tumor Necrosis Factor-Alpha–Neutralizing Antibody: A Possible Healthcare-Associated Case? , 2003, Infection Control & Hospital Epidemiology.
[36] L. Punzi,et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate , 2003, Annals of the rheumatic diseases.
[37] Pilar Barrera,et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. , 2003, Arthritis and rheumatism.
[38] E. Chung,et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.
[39] H. Paulus,et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.
[40] S. Plevy,et al. The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.
[41] A. Aouba,et al. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. , 2003, Rheumatology.
[42] M. Braun,et al. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.
[43] A. Widmer,et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003, Rheumatology.
[44] N. Rothfield,et al. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[45] F. Frizelle,et al. Pregnancy and exposure to infliximab (anti‐tumor necrosis factor‐alpha monoclonal antibody) , 2003, Journal of gastroenterology and hepatology.
[46] W. Tyler,et al. Worsening injection site reactions with continued use of etanercept. , 2003, Journal of drugs in dermatology : JDD.
[47] E. Veys,et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.
[48] V. Leone,et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. , 2003, Clinical and experimental rheumatology.
[49] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[50] N. Gaylis. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. , 2003, The Journal of rheumatology.
[51] E. Chakravarty,et al. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. , 2003, The Journal of rheumatology.
[52] M. Braun,et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. , 2003, Arthritis and rheumatism.
[53] O. Meyer,et al. Anti-TNF-α-induced systemic lupus syndrome , 2003, Clinical Rheumatology.
[54] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[55] S. Anker,et al. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.
[56] M. Greene,et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.
[57] A. Taggart,et al. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. , 2002, The Ulster medical journal.
[58] S. Gabriel,et al. Predictors of infection in rheumatoid arthritis. , 2002, Arthritis and rheumatism.
[59] S. Gabriel,et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.
[60] D. M. Johnson,et al. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. , 2002, Rheumatology.
[61] P. V. van Riel,et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. , 2002, Rheumatology.
[62] J. Richert,et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.
[63] N. Sicotte,et al. Onset of multiple sclerosis associated with anti-TNF therapy , 2001, Neurology.
[64] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[65] W. Robinson,et al. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? , 2001, Arthritis and rheumatism.
[66] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[67] Richard W. Martin,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.
[68] A. Markham,et al. Infliximab: a review of its use in the management of rheumatoid arthritis. , 2000, Drugs.
[69] T. Schaible,et al. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment , 1999, Annals of the rheumatic diseases.
[70] D. Furst,et al. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. , 1999, Rheumatology.
[71] L. Garrison,et al. Etanercept: therapeutic use in patients with rheumatoid arthritis , 1999, Annals of the rheumatic diseases.
[72] S. Hanauer. Review article: safety of infliximab in clinical trials , 1999, Alimentary pharmacology & therapeutics.
[73] D. Faulds,et al. Etanercept: a review of its use in rheumatoid arthritis. , 1999, Drugs.
[74] C. Pritchard,et al. Etanercept and hepatitis C. , 1999, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[75] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[76] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[77] L. Moreland,et al. Tumor necrosis factor inhibitors for rheumatoid arthritis. , 1999, Bulletin on the rheumatic diseases.
[78] N. Lane,et al. Osteoporosis: diagnosis, prevention, and treatment of established disease. , 1999, Bulletin on the rheumatic diseases.
[79] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[80] A. Kavanaugh. ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITIS , 1998 .
[81] Lars Klareskog,et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study , 1998, BMJ.
[82] L. Moreland,et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. , 1996, The Journal of rheumatology.
[83] R. Davey,et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. , 1996, The Journal of infectious diseases.
[84] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[85] J. Woody,et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.
[86] J. Ghrayeb,et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.
[87] D. Symmons,et al. Cancer morbidity in rheumatoid arthritis. , 1984, Annals of the rheumatic diseases.
[88] J. Lyford. The British Society for Rheumatology. , 1983, Annals of the rheumatic diseases.
[89] T. Hakulinen,et al. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. , 1978, Journal of chronic diseases.